(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 March 2021 (18.03.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/048736 A1

(51) International Patent Classification:
A61K 31/4985 (2006.01) *A61K 31/519* (2006.01)
A61K 31/506 (2006.01) *A61P 17/00* (2006.01)

(21) International Application Number:
PCT/IB2020/058333

(22) International Filing Date:
08 September 2020 (08.09.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/899,133 11 September 2019 (11.09.2019) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **FENSOME, Andrew**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **GERSTENBERGER, Brian Stephen**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **OWEN, Dafydd Rhys**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: TREATMENT OF HIDRADENITIS WITH JAK INHIBITORS

(57) Abstract: Methods for treating hidradenitis suppurtiva using compounds and analogues which inhibit certain kinases including Janus Kinase (JAK).

WO 2021/048736 A1